- France's Adocia ( OTC:ADOCY ) said its Chinese partner Tonghua Dongbao noted that a phase 1 trial of BioChaperone Lispro insulin (THDB0206 in China) met its main goal.
- The company added that BioChaperone Lispro was compared to Eli Lilly's ( NYSE: LLY ) Humalog (insulin lispro), and pharmacokinetic/pharmacodynamic properties of BioChaperone were significantly faster.
- BioChaperone also showed good tolerability and safety profiles, according to the company.
- The phase 1 trial evaluated a single dose of BioChaperone in healthy Chinese people. The main goal of the study was to evaluate whether a BioChaperone injection has a faster absorption and onset of action compared to a Humalog injection, the company noted.
- Adocia said ongoing phase 3 studies are the only remaining clinical activities planned before filing for regulatory approval in China.
- The company added that BioChaperone is expected to be the first analog of ultra-rapid insulin to be marketed in China by a Chinese company.
- Adocia had licensed BioChaperone to Tonghua Dongbao for China and major Asian territories.
For further details see:
Adocia, Tonghua's BioChaperone Lispro insulin shows promise in phase 1 trial